Should You Buy UnitedHealth Group (UNH) Stock Before October 28?

UnitedHealth Group (UNH), the largest U.S. health insurer, has experienced a 37% stock decline over the past year, attributed to a DOJ Medicare fraud investigation and CEO turnover, yet its dividend yield has risen to 2.5%. Despite these headwinds, the company is pursuing cost-cutting initiatives, including AI, and planning premium increases for 2026/2027, contributing to a recent 16% stock rebound. With a P/E ratio of 15 significantly below its five-year average and a substantial stake held by Berkshire Hathaway, the current valuation suggests a potential long-term buying opportunity ahead of its upcoming earnings report.

Analysis

UnitedHealth Group (UNH) is navigating significant headwinds, reflected in a 37% stock price decline over the past year, primarily driven by a Department of Justice investigation into potential Medicare fraud and a recent CEO transition. These events have created a notable governance and legal overhang. However, this price compression has elevated the dividend yield to 2.5% and the total shareholder yield, including buybacks, to 5.5%. Counterbalancing the risks are several bullish factors, including a recent 16% stock rally in the past month, strategic initiatives to trim costs using artificial intelligence, and planned premium increases for 2026 and 2027. The stock's valuation appears attractive, with a price-to-earnings ratio of 15 sitting well below its five-year average of 23.6 and a price-to-sales ratio of 0.75 below its 1.29 average. A nearly $1.6 billion stake by Berkshire Hathaway provides a strong vote of confidence, while the upcoming October 28 earnings report serves as a critical near-term catalyst that will test the emerging positive investor sentiment.

Key Decisions for Investors

• Investors should weigh the compelling valuation, with a P/E of 15 and a 5.5% total yield, against the material uncertainty stemming from the DOJ investigation and management turnover.
• The upcoming October 28 earnings release is a pivotal event; consider that a positive report could trigger a significant repricing, while a disappointment may present an even more attractive entry point.
• For long-term investors, the combination of cost-cutting initiatives, planned premium hikes, and Berkshire Hathaway's endorsement suggests the current weakness could represent a strategic buying opportunity, provided the company successfully navigates its legal challenges.
• Given the stock's recent 16% rebound, momentum-focused investors should monitor if the price can overcome resistance created by its longer-term downtrend, using the earnings report as a key validation point.